Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
As Arrowhead prepares to unveil key data in alpha-1 antitrypsin deficiency, its life is made easier by Vertex’s second failure in the disease.
A small molecule for alpha-1 antitrypsin deficiency faces a key clinical test, and its chances of success aren’t good.
The company’s lead cystic fibrosis asset fails, shifting the focus to the Sanofi-partnered Covid-19 vaccine.
At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.